{
    "clinical_study": {
        "@rank": "165010", 
        "brief_summary": {
            "textblock": "High dose methotrexate with leucovorin rescue has demonstrated activity in numerous\n      malignancies.  Although high dose methotrexate is generally well tolerated, unpredictable\n      life-threatening toxicity can occur.  For patients who have markedly delayed clearance of\n      methotrexate secondary to renal dysfunction, therapeutic options are few and are of limited\n      efficacy.  Carboxypeptidase-G2 inactivates methotrexate by hydrolyzing its C-terminal\n      glutamate residue.  Carboxypeptidase-G2 could be used to rescue patients with renal\n      dysfunction and delayed methotrexate excretion, as it provides an alternative to renal\n      clearance as a route of elimination."
        }, 
        "brief_title": "A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction", 
        "completion_date": "January 2001", 
        "condition": "Kidney Diseases", 
        "condition_browse": {
            "mesh_term": "Kidney Diseases"
        }, 
        "detailed_description": {
            "textblock": "High dose methotrexate with leucovorin rescue has demonstrated activity in numerous\n      malignancies.  Although high dose methotrexate is generally well tolerated, unpredictable\n      life-threatening toxicity can occur.  For patients who have markedly delayed clearance of\n      methotrexate secondary to renal dysfunction, therapeutic options are few and are of limited\n      efficacy.  Carboxypeptidase-G2 inactivates methotrexate by hydrolyzing its C-terminal\n      glutamate residue.  Carboxypeptidase-G2 could be used to rescue patients with renal\n      dysfunction and delayed methotrexate excretion, as it provides an alternative to renal\n      clearance as a route of elimination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients of any age at risk for life-threatening toxicity following MTX administration\n        secondary to delayed drug excretion as defined by:\n\n        Plasma MTX concentration at least 10 micromoles/liter more than 42 hours after the start\n        of the MTX infusion; OR\n\n        Creatinine at least 1.5 times the upper limit of normal or creatinine clearance less than\n        60 ml/sqm/min and delayed MTX excretion documented by plasma MTX concentration\n        measurements (at least 2 standard deviations above the mean) at least 12 hours following\n        MTX administration."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "10", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001298", 
            "org_study_id": "920134", 
            "secondary_id": "92-C-0134"
        }, 
        "intervention": {
            "intervention_name": "carboxypeptidase-G2", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "keyword": [
            "Antibody", 
            "DAMPA", 
            "Enzyme", 
            "Kidney", 
            "Pharmacokinetics", 
            "Thymidine", 
            "Toxicity"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "1634927", 
                "citation": "Adamson PC, Balis FM, McCully CL, Godwin KS, Poplack DG. Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. J Clin Oncol. 1992 Aug;10(8):1359-64."
            }, 
            {
                "PMID": "8625136", 
                "citation": "Widemann BC, Hetherington ML, Murphy RF, Balis FM, Adamson PC. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer. 1995 Aug 1;76(3):521-6."
            }, 
            {
                "PMID": "9164227", 
                "citation": "Widemann BC, Balis FM, Murphy RF, Sorensen JM, Montello MJ, O'Brien M, Adamson PC. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol. 1997 May;15(5):2125-34."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001298"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "March 1992", 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2000"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}